GURU.Markets stock price, segment price, and overall market index valuation
The company's share price GRAIL Inc.
The value of GRAIL, a blood-based early cancer detection company, is determined by the potential of its Galleri test. Following its spinoff from Illumina, its stock price will reflect the pace of commercialization of this revolutionary test and insurance companies' decisions on coverage.
Share prices of companies in the market segment - Cancer analysis
The value of GRAIL, a blood-based early cancer diagnostic company, is driven by the potential of its Galleri test. We classify it in the Cancer Analysis sector, and the chart below reflects the dynamics of this cutting-edge and promising biotech sector.
Broad Market Index - GURU.Markets
GRAIL is a healthcare company focused on early cancer detection with its Galleri blood-based test. Its breakthrough technology makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how GRAIL compares to it.
Change in the price of a company, segment, and market as a whole per day
GRAL - Daily change in the company's share price GRAIL Inc.
The volatility of GRAIL, a company developing early cancer detection tests using blood tests, reflects the enormous expectations and risks of the biotech sector. Change_co measures sensitivity to research news. This metric is the basis for analysis of the innovative oncology diagnostics sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Cancer analysis
The molecular diagnostics sector, in which GRAIL, Inc. is a pioneer, is highly dynamic. This chart reflects the average volatility of the industry. It serves as a benchmark for assessing how sensitive GRAIL's early cancer detection business is to development and competitive news.
Daily change in the price of a broad market stock, index - GURU.Markets
GRAIL, a subsidiary of Illumina, is a leader in blood-based early cancer detection tests. Its technology has the potential to revolutionize medicine. The chart below shows the volatility in the biotech sector, reflecting the enormous expectations and risks associated with GRAIL.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization GRAIL Inc.
Following its spinoff from Illumina, GRAIL demonstrated to the market the potential of its revolutionary blood-based test for early cancer detection. Its year-over-year share price performance, shown in the chart, reflects investors' faith in the future of precision medicine.
Annual dynamics of market capitalization of the market segment - Cancer analysis
Following its upcoming spinoff from Illumina, GRAIL will become a public company focused on early cancer diagnosis using blood tests. Its performance will reflect investors' faith in its revolutionary Galleri technology. The chart will show how its enormous potential and high risks compare to the diagnostics sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
GRAIL, a developer of early cancer diagnostic tests, was spun out of Illumina. Analysis of its market performance as a standalone company will reflect investors' faith in the revolutionary potential of its technology. This isn't about economics, but rather a long-term bet on the future of medicine, one fraught with enormous risks.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization GRAIL Inc.
The value of GRAIL, a company in the field of early cancer diagnostics, will depend on the adoption of its tests. Monthly fluctuations on the chart will reflect the growth of Galleri tests performed and, crucially, insurance companies' decisions to include this test in standard coverage.
Monthly dynamics of market capitalization of the market segment - Cancer analysis
GRAIL, Inc. is a healthcare company focused on early cancer detection with a single blood test. Its sector dynamics, shown in the chart, reflect the enormous promise and risks in cancer diagnostics. Against this backdrop, one can assess how the revolutionary potential of the Galleri test and its progress in commercialization are impacting perceptions of the company.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
GRAIL is developing tests for early cancer diagnosis using blood tests (liquid biopsy). This is one of the most promising areas in medicine. The full market chart allows us to assess how much investors believe in GRAIL's long-term potential, which could allow its shares to rise regardless of general sentiment, driven by hopes for a revolution in oncology.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization GRAIL Inc.
GRAIL, a company developing blood-based tests for early cancer detection, is at the forefront of medical science. Its weekly stock price is extremely volatile, driven by news about clinical data, regulatory approvals, and the introduction of its tests into clinical practice.
Weekly dynamics of market capitalization of the market segment - Cancer analysis
GRAIL, Inc., a pioneer in early cancer diagnosis, is part of the volatile biotech sector. This chart compares its performance with the industry, demonstrating how its unique technological breakthroughs and regulatory news allow it to move independently of overall biotech sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
GRAIL is a company focused on early cancer detection using blood tests (liquid biopsy). Its shares exist in a world of their own, where research data is king. The chart shows that GRAIL's performance is almost uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
GRAL - Market capitalization of the company GRAIL Inc.
GRAIL's market cap is a financial bet on the holy grail of oncology—early cancer diagnosis using blood tests. This company's stock price reflects investors' faith in the revolutionary potential of its technology. Its dynamics are a barometer of hope for a future where deadly diseases can be detected and treated at the earliest stages.
GRAL - Share of the company's market capitalization GRAIL Inc. within the market segment - Cancer analysis
GRAIL is a healthcare company focused on early cancer detection using blood tests. Its high market capitalization reflects the enormous potential of its Galleri technology to change the paradigm of cancer treatment. The chart below shows the enormous market bet on the success of this diagnostic revolution.
Market capitalization of the market segment - Cancer analysis
GRAIL, a subsidiary of Illumina, is developing tests for early cancer detection using blood tests. The chart below shows the market capitalization of the entire biotech sector. Its dynamics reflect investors' high hopes for a breakthrough in oncology, where GRAIL could become a game-changer.
Market capitalization of all companies included in a broad market index - GURU.Markets
GRAIL is a company with the ambitious goal of early cancer detection using blood tests. Its market capitalization reflects one of the greatest hopes of modern medicine. Its market value represents a financial bet that this technology will change the paradigm of cancer treatment.
Book value capitalization of the company, segment and market as a whole
GRAL - Book value capitalization of the company GRAIL Inc.
For GRAIL, an early cancer diagnostics company, its book value lies in its cutting-edge laboratories and diagnostic equipment. The chart below shows how the company is investing in its scientific and technological arsenal. Growth in this arsenal means creating the material foundation for a revolution in oncology.
GRAL - Share of the company's book capitalization GRAIL Inc. within the market segment - Cancer analysis
GRAIL develops tests for the early detection of cancer using blood tests. Its core business is its advanced, high-performance laboratories. The asset share chart shows how the company invests in the unique and capital-intensive physical infrastructure that is the heart of its diagnostic technology.
Market segment balance sheet capitalization - Cancer analysis
GRAIL develops tests for the early detection of cancer. Its business is built on cutting-edge science and complex laboratory processes requiring specialized equipment. The book value chart shows how investments in science-intensive assets form the foundation for the creation of breakthrough medical technologies.
Book value of all companies included in the broad market index - GURU.Markets
GRAIL's book value is the material foundation of a revolution in cancer diagnostics. The company's assets are not hospitals, but cutting-edge DNA sequencing labs equipped with state-of-the-art equipment and powerful data centers. The chart shows the physical capital invested in technology capable of detecting cancer with a single blood test.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - GRAIL Inc.
GRAIL is engaged in early cancer diagnosis using blood tests. The company's book value doesn't reflect its core value—its unique technology and the data it collects. Its market capitalization represents a gigantic bet by investors that its tests will revolutionize medicine and save millions of lives. It's a valuation of the future, not the present.
Market to book capitalization ratio in a market segment - Cancer analysis
GRAIL develops tests for early cancer diagnosis, and its core value lies in its scientific data and technology. This chart illustrates how much its market capitalization, based on its hopes for a revolutionary product, exceeds its current book value. It's a classic example of a breakthrough biotech company's valuation.
Market to book capitalization ratio for the market as a whole
GRAIL develops tests for early cancer detection. The company's value lies in its unique technology and data, not in its physical assets. Its market capitalization reflects its enormous promise of revolutionizing medicine. This chart illustrates the enormous gap between book value and market valuation, typical of disruptive biotech companies.
Debts of the company, segment and market as a whole
GRAL - Company debts GRAIL Inc.
For GRAIL, a company focused on early cancer diagnosis, debt is a critical resource for funding research and development. This chart shows the capital required to conduct extensive clinical trials and bring its innovative tests to market. This represents a long-term investment in a revolutionary medical technology.
Market segment debts - Cancer analysis
GRAIL specializes in developing early cancer diagnostic tests using blood analysis. This is a cutting-edge and capital-intensive area of medicine, where debt can be used to finance large-scale clinical trials and bring the product to market. The chart below demonstrates the company's debt strategy compared to other innovators in the biotech sector.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio GRAIL Inc.
GRAIL is developing tests for early cancer detection—a revolutionary but extremely capital-intensive field. This chart shows how the company is funding its large-scale research and clinical trials. Investors can use this information to assess the financial risks involved in the long journey to commercialization and regulatory approval.
Market segment debt to market segment book capitalization - Cancer analysis
GRAIL is a company focused on early cancer detection using blood testing. This technology has the potential to revolutionize medicine, but it requires massive investments in research and clinical validation. This chart shows the overall debt burden in the biotech sector, providing insight into how the company is funding its ambitious and capital-intensive scientific goals.
Debt to book value of all companies in the market
GRAIL aims to revolutionize cancer diagnostics, which requires colossal investment. This chart reflects the overall debt burden of the economy. It helps us understand how global financial conditions and capital availability affect the ability of GRAIL and other disruptive biotech companies to finance their long-term, capital-intensive missions.
P/E of the company, segment and market as a whole
P/E - GRAIL Inc.
GRAIL is developing tests for early cancer detection using blood tests. This chart reflects the enormous hopes placed on the company in the healthcare sector. Its high value demonstrates investors' faith in the revolutionary potential of this technology, which could save millions of lives and generate billions in revenue, despite the lack of significant profits today.
P/E of the market segment - Cancer analysis
GRAIL operates in the innovative early cancer diagnostics sector. This chart shows the average P/E for this cutting-edge industry, which is full of high expectations. If a company's P/E is above this average, it means investors consider its blood-based cancer detection technology more accurate and commercially promising than competing diagnostic companies.
P/E of the market as a whole
GRAIL is developing tests for early cancer detection using blood tests, which could revolutionize medicine. The company's valuation is an investment in the future of diagnostics. This chart shows the overall market propensity to support long-term innovation. It helps determine whether GRAIL is receiving funding based on general optimism or whether its technology is a game-changer in its own right.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company GRAIL Inc.
GRAIL is a healthcare company focused on early cancer detection using blood tests. This chart reflects investors' long-term expectations for the widespread adoption of its tests in medical practice. The valuation is based not on current revenue, but on forecasts for a revolution in cancer diagnostics and the potential for a multi-billion dollar market.
%20P%2FE%20GRAIL%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-GRAIL-Inc.&v=1772585988071 "Chart of the company's future (projected) P/E GRAIL Inc.")
Future (projected) P/E of the market segment - Cancer analysis
GRAIL is developing blood-based tests for early cancer detection, which could revolutionize diagnostics. This chart compares the company's future profitability expectations with those of the medical technology sector. It demonstrates the extent to which investors believe in the commercial potential of its breakthrough Galleri technology and its potential to become a standard in oncology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-analysis&v=1772585988104 "Future (projected) P/E graph of the market segment - Cancer analysis")
Future (projected) P/E of the market as a whole
GRAIL is a healthcare company focused on early cancer detection using blood tests. GRAIL's success depends on the widespread adoption of its tests, which requires significant investment in research and marketing. Optimistic market expectations, illustrated in this chart, are driving capital flows into breakthrough medical technologies and accelerating their adoption.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772585988116 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit GRAIL Inc.
GRAIL is a healthcare company focused on early cancer detection using blood tests. The company's financial health is determined by its investments in research and development, as well as the commercialization of its tests. This chart shows the financial trajectory of a medical diagnostics pioneer, where research and development expenditures precede potential future revenue.
Profit of companies in the market segment - Cancer analysis
GRAIL is at the forefront of the fight against cancer, developing early diagnostic tests based on blood analysis. The biotech sector's total revenue, as reflected here, is directly dependent on such breakthrough innovations. Successful implementation of GRAIL's technology has the potential not only to save lives but also to create a new multi-billion dollar market, radically changing the financial landscape of the industry.
Overall market profit
GRAIL is a company whose mission is to detect cancer early using blood tests. This biotech industry attracts massive investment regardless of short-term economic fluctuations. GRAIL's success has the potential to transform healthcare and exemplifies how capital is being directed toward solving fundamental human problems.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company GRAIL Inc.
GRAIL is a healthcare company specializing in early cancer diagnosis using blood tests. The revenue projections presented here reflect market expectations regarding the commercialization of its tests. Growth depends on regulatory approval, inclusion of the tests in insurance coverage, and widespread adoption in clinical practice.
%20profit%20of%20the%20company%20GRAIL%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-GRAIL-Inc.&v=1772585988181 "Graph of future (projected) profit of the company GRAIL Inc.")
Future (predicted) profit of companies in the market segment - Cancer analysis
GRAIL is a company focused on early cancer detection using blood testing. Its technology has the potential to revolutionize approaches to oncology. This chart shows overall profitability forecasts for the entire cancer testing sector. It reflects the enormous market expectations for companies capable of making a breakthrough in the fight against one of humanity's leading diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-analysis&v=1772585988204 "Graph of future (predicted) profits of companies in a market segment - Cancer analysis")
Future (predicted) profit of the market as a whole
GRAIL is a healthcare company focused on early cancer detection using blood tests. Demand for such breakthrough technologies is enormous and largely unaffected by short-term economic fluctuations. However, as this chart shows, the overall investment climate influences the willingness of healthcare systems and insurance companies to cover the costs of expensive innovative tests.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772585988208 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - GRAIL Inc.
GRAIL is a healthcare company focused on early cancer detection using blood tests. Given its potential to transform medicine, this chart is particularly revealing. It reflects the enormous expectations of investors and the premium they are willing to pay for every dollar of revenue, believing in the revolutionary potential of its diagnostic tests.
P/S market segment - Cancer analysis
GRAIL is at the forefront of the fight against cancer, developing tests for the early detection of cancers using blood samples. Their technology has the potential to change the diagnostic paradigm, saving lives through timely treatment. This chart shows the high market valuation that the breakthrough medical technology sector can command for revenue, reflecting investor confidence in the company's revolutionary potential.
P/S of the market as a whole
GRAIL is a healthcare company focused on early cancer detection using blood testing. Its technology has the potential to revolutionize oncology. The company's valuation is based on future commercial prospects. This chart shows the overall market valuation of current revenue, highlighting how expectations for GRAIL exceed its current financial performance.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company GRAIL Inc.
GRAIL, Inc. is focused on developing blood-based tests for early cancer detection. For such a disruptive company, this chart shows investor estimates of its future revenue from commercialization of these tests. It reflects the market's enormous expectations for a revolution in cancer diagnostics and its belief in GRAIL's ability to become a leader in this niche.
%20P%2FS%20GRAIL%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-GRAIL-Inc.&v=1772585988349 "The graph of the company's future (projected) P/S GRAIL Inc.")
Future (projected) P/S of the market segment - Cancer analysis
GRAIL is a healthcare company whose mission is to detect cancer early with a single blood test. The data presented compares the company's estimated future revenue with peers in the sector. A very high valuation may indicate confidence in the revolutionary potential of its Galleri technology, while a lower valuation suggests regulatory barriers and a long road to widespread adoption.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-analysis&v=1772585988452 "Future (projected) P/S market segment graph - Cancer analysis")
Future (projected) P/S of the market as a whole
GRAIL is developing tests for the early detection of cancer using blood tests. The company's future depends on the widespread adoption of its technologies in medical practice. This graph, reflecting investor revenue expectations for the entire market, demonstrates their shared belief in breakthrough medical technologies and their willingness to fund companies that can transform healthcare.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772585988475 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales GRAIL Inc.
This chart shows the commercialization of GRAIL's breakthrough early cancer diagnostic technology. Revenue is generated from sales of its flagship product, the Galleri blood test, which can detect over 50 types of cancer at an early stage. The growth of this indicator reflects the degree of adoption of this innovative test in the healthcare system.
Sales of companies in the market segment - Cancer analysis
GRAIL is a healthcare company focused on early cancer detection through blood testing. Its technology has the potential to change the paradigm in oncology, moving from diagnostics to screening. This chart shows the total revenue of the oncology testing market, demonstrating the enormous potential of the segment GRAIL aims to transform.
Overall market sales
GRAIL, Inc. develops blood-based tests for early cancer detection. Demand for its innovative products depends on their adoption in the healthcare system and the population's ability to pay. This graph, reflecting overall economic well-being, shows the potential willingness of society and governments to invest in expensive but breakthrough medical technologies that save lives.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company GRAIL Inc.
GRAIL, Inc. is a healthcare company that has revolutionized early cancer detection using blood testing. As a pioneer in its field, its future revenue depends on widespread adoption of the test and its coverage by insurance companies. This chart represents analysts' long-term view of the commercial potential of this breakthrough, life-saving technology.
%20sales%20of%20the%20company%20GRAIL%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-GRAIL-Inc.&v=1772585988648 "Schedule of future (projected) sales of the company GRAIL Inc.")
Future (projected) sales of companies in the market segment - Cancer analysis
GRAIL is a healthcare company focused on early cancer detection using blood testing. The forecast chart shows the potential revenue from their flagship Galleri test and other diagnostic products. This demonstrates the size of the market analysts see for this breakthrough technology and the expectations for its commercialization.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-analysis&v=1772585988672 "Schedule of future (projected) sales of companies in the market segment - Cancer analysis")
Future (projected) sales of the market as a whole
The economic growth forecasts presented here are important for GRAIL. The company develops tests for the early detection of cancer. The implementation of such costly innovations in the healthcare system depends on its financial capacity and willingness to invest in preventive medicine, which becomes more likely during an economic recovery.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772585988738 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality GRAIL Inc.
GRAIL is at the forefront of medicine, developing blood tests for early cancer detection. This graph reflects the stage of major investment in a technology that could transform healthcare. Negative values indicate high research and marketing costs, and future profitability depends on widespread adoption of the test and its coverage by insurance companies.
Market segment marginality - Cancer analysis
GRAIL is a healthcare company focused on early cancer detection using blood tests (liquid biopsies). Its profitability depends on the widespread adoption of its tests and reimbursement from insurance companies. This chart shows the average profitability in the sector. It helps assess the potential commercial success of GRAIL's revolutionary technology.
Market marginality as a whole
GRAIL is a healthcare company focused on early cancer detection through blood testing. Demand for its expensive tests depends on the ability of the population and insurance companies to pay. This graph reflects overall economic well-being, which influences the willingness of individuals and healthcare systems to invest in preventive medicine.
Employees in the company, segment and market as a whole
Number of employees in the company GRAIL Inc.
GRAIL is developing a revolutionary technology for early cancer detection using blood testing. This graph shows the size of the scientific and clinical team advancing this cutting-edge technology. The growth in the graph reflects the scaling of research, clinical trials, and preparation for commercial launch, which requires significant human capital.
Share of the company's employees GRAIL Inc. within the market segment - Cancer analysis
GRAIL has set an ambitious goal: early cancer detection using blood tests. Achieving this mission requires engaging the best minds in genetics, oncology, and bioinformatics. This chart shows what proportion of the entire scientific community in this field is working at GRAIL. It reflects the scale of its research and the faith of its investors in the company's breakthrough technology.
Number of employees in the market segment - Cancer analysis
GRAIL is a healthcare company focused on early cancer detection using blood tests. The employment dynamics in the oncology diagnostics sector, which can be assessed using this chart, are critically important. The growing number of specialists indicates breakthroughs in research and growing demand for early diagnostic technologies, confirming the enormous market potential of GRAIL.
Number of employees in the market as a whole
GRAIL is a healthcare company focused on early cancer detection using blood tests. Their growth depends on breakthroughs in biotechnology and the adoption of their tests in clinical practice. While this chart shows general trends, for GRAIL, scientific progress and regulatory approval are key, shaping their HR strategy.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company GRAIL Inc. (GRAL)
GRAIL is a healthcare company specializing in early cancer detection. Its value lies in its breakthrough blood testing technology. This chart reflects the market's enormous bet on its scientific potential. A small team of researchers and technicians is creating intellectual property with enormous potential value.
%20of%20the%20company%20GRAIL%20Inc.%20(GRAL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-GRAIL-Inc.-GRAL&v=1772585988876 "Chart of market capitalization per employee (in thousands of dollars) of the company GRAIL Inc. (GRAL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer analysis
GRAIL is a life sciences company focused on early cancer detection using a single blood test (the Galleri test). This is a breakthrough technology in the field of liquid biopsy. Their value lies in their unique technology and the data they collect, not in their staff. This indicator shows how the market values such revolutionary R&D platforms.
%20by%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-analysis&v=1772585988885 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer analysis")
Market capitalization per employee (in thousands of dollars) for the overall market
GRAIL specializes in developing blood-based early cancer detection tests. This is a cutting-edge field in medicine, where intellectual property and scientific data are key assets. This chart shows the company's enormous market valuation per employee, as investors evaluate the technology's potential to save millions of lives and transform healthcare.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772585988889 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company GRAIL Inc. (GRAL)
GRAIL is at the forefront of medicine, developing tests for the early detection of cancer using blood samples. This mission requires enormous investments in R&D and clinical trials. This chart should be interpreted as an "investment in the future": it shows how much the company spends (negative profit) on each scientist to bring about the era of preventive oncology.
%20Chart%20GRAIL%20Inc.%20(GRAL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-GRAIL-Inc.-GRAL&v=1772585988952 "Company Profit Per Employee (in thousands of dollars) Chart GRAIL Inc. (GRAL)")
Profit per employee (in thousands of dollars) in the market segment - Cancer analysis
GRAIL is an R&D company developing a "blood test" (Galleri) for the *early* detection of dozens of cancers. This graph shows the benchmark for the "Cancer Analysis Sector." In this sector, the benchmark is *deeply negative*. This is a "pure" R&D race. Profit per employee (scientist) is the goal of the future; today, it's about burning billions on "clinical trials."
%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-analysis&v=1772585988975 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer analysis")
Profit per employee (in thousands of dollars) for the market as a whole
GRAIL is a life science company whose mission is early cancer detection with a single blood test (liquid biopsy technology). This breakthrough diagnostic technology is based on sophisticated R&D and laboratory processes. This chart allows you to evaluate how this model, which requires highly qualified scientific personnel, compares in profitability with market standards.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772585988988 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee GRAIL Inc. (GRAL)
GRAIL, a healthcare company, is focused on early cancer detection using blood tests. While its technology is still in the implementation phase, revenue per employee reflects progress in commercialization. This chart shows how scientific advancements and partnerships with healthcare systems are starting to generate revenue as they move toward mass adoption.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-GRAIL-Inc.-GRAL&v=1772585989018 "Sales chart per company employee GRAIL Inc. (GRAL)")
Sales per employee in the market segment - Cancer analysis
GRAIL is the biotech behind the Galleri blood-based early detection test for several types of cancer. This breakthrough technology requires significant R&D investment. This chart shows the company's progress toward commercialization. The productivity of their team of scientists and doctors is measured by their ability to transform a scientific discovery into a large-scale medical product.
Sales per employee for the market as a whole
GRAIL (GRAL) is a life sciences company whose mission is early cancer detection with a single blood test (the "Gallbladder" test). This is a revolutionary diagnostic technology. The company is currently in the commercialization phase and conducting large-scale clinical trials. This graph reflects their significant investment in R&D and marketing. This figure will grow as their tests gain wider acceptance.
Short shares by company, segment and market as a whole
Shares shorted by company GRAIL Inc. (GRAL)
GRAIL is a life sciences company whose mission is early cancer detection. They developed the "Galleri" test, designed to detect over 50 types of cancer with a single blood test (liquid biopsy). This chart reflects bearish bets. Skeptics may question the test's accuracy and clinical utility, and point to the formidable obstacles to gaining widespread regulatory approval and insurance coverage.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-GRAIL-Inc.-GRAL&v=1772585989099 "Short Shares Chart for the Company GRAIL Inc. (GRAL)")
Shares shorted by market segment - Cancer analysis
GRAIL (GRAL) develops early cancer detection tests using blood (liquid biopsy), such as the Galleri test. This is a breakthrough technology in diagnostics. This chart shows the overall volume of bets against the oncology diagnostics sector. Investors betting against the industry may be unsure how quickly insurance companies will cover such expensive tests or fear intense competition.
Shares shorted by the overall market
GRAIL (GRAL) is a biotech (early cancer detection). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives GRAL of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator GRAIL Inc. (GRAL)
GRAIL is a company developing tests for early cancer detection using blood tests (so-called "liquid biopsy"). It is one of the most breakthrough technologies in medicine. This chart measures investor hope. It shows when the stock is "overbought" on expectations of a revolution in diagnostics or "oversold" due to doubts about accuracy and approval timelines.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-GRAIL-Inc.-GRAL&v=1772585989162 "RSI 14 indicator chart for the company's stock GRAIL Inc. (GRAL)")
RSI 14 Market Segment - Cancer analysis
GRAIL is a biotech company that developed Galleri, a breakthrough blood test (a "liquid biopsy") capable of detecting over 50 types of cancer in their early stages, before symptoms appear. This graph measures the collective excitement in the oncology diagnostics sector. It helps us understand whether the entire segment is overheated by expectations of a screening revolution.
RSI 14 for the overall market
GRAIL (GRAL) develops tests for early cancer detection. This graph is its lifeline. Its business is pure R&D. During periods of euphoria, investors are willing to fund the "future of medicine." In moments of panic, they flee unprofitable biotech companies, and GRAIL risks running out of funds for its breakthrough but expensive research.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GRAL (GRAIL Inc.)
GRAIL is the company behind the breakthrough Galleri liquid biopsy test, designed for the early detection of dozens of cancer types using blood tests. This chart shows the average analyst forecast. Their targets are based on the pace of commercialization of the Galleri test, securing insurance coverage, and the long-term potential of the early diagnostics market.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GRAL-GRAIL-Inc.&v=1772585989237 "A chart showing analyst consensus forecasts for the expected stock price. GRAL (GRAIL Inc.)")
The difference between the consensus estimate and the actual stock price GRAL (GRAIL Inc.)
GRAIL (GRAL) is the company behind the Galleri test, which promises the holy grail of medicine: early detection of dozens of cancer types with a single blood test. This chart is a barometer of the technology's hopes. It measures the gap between the price and the consensus target, reflecting the (often enormous) potential analysts see in their breakthrough diagnostics.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GRAL-GRAIL-Inc.&v=1772585989269 "A chart showing the difference between the consensus forecast and the actual stock price. GRAL (GRAIL Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer analysis
GRAIL is a pioneer in early cancer diagnostics using blood testing (the Galleri test). It was acquired and then spun off from Illumina due to regulatory issues. This chart shows analysts' general expectations for the oncology diagnostics sector. It reflects whether experts believe expensive screening tests will be widely adopted.
Analysts' consensus forecast for the overall market share price
GRAIL is a cancer hunter. They are a pioneer in liquid biopsy, trying to create a single test (Galleri) for the early detection of 50+ types of cancer. This schedule, reflecting expert expectations, influences them. In a recession (pessimism), insurers (payers) are reluctant to approve new, expensive, preventative tests.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index GRAIL Inc.
GRAIL is a company pursuing the Holy Grail of medicine: early cancer detection. Their flagship test, Galleri, is designed to detect dozens of cancer types with a single blood test. This chart is a pure indicator of biotech expectations. It doesn't reflect profits, but rather an aggregated assessment of their scientific data and the enormous potential of the early diagnostics market.
AKIMA Market Segment Index - Cancer analysis
GRAIL (GRAL) is a pioneer in liquid biopsy (like Guardant); the company (owned by Illumina) has developed a revolutionary blood test (Galleri) capable of detecting dozens of types of cancer at an early stage. This summary metric evaluates R&D. The graph shows the average value for the segment. This is the benchmark: how does this breakthrough (early cancer detection) technology (GRAL) differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
GRAIL is a pioneer in early cancer detection. Its Galleri test can detect multiple types of cancer with a single blood test. It was spun off from Illumina. This chart, reflecting the market average, is just a backdrop. It helps assess how this innovative but unprofitable company stacks up against overall economic trends and physician adoption of its technology.
